← Back to Search

18F-DCFPyL Injection for Cancer

Phase 1
Waitlist Available
Led By Steven Rowe, M.D., Ph.D
Research Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights

Study Summary

This trial will use a new imaging agent, 18F-DCFPyL, to detect none prostate cancer solid malignancies and schwannoma tumors using PET/CT.

Eligible Conditions
  • Cancer
  • Schwannoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Determine feasibility of using 18F-DCFPyL to detect cancer

Side effects data

From 2018 Phase 2 & 3 trial • 385 Patients • NCT02981368
1%
pyelonephritis, acute
1%
spinal cord compression
1%
atrial fibrillation
1%
hyperkalaemia
1%
coronary artery disease
1%
Lower gastrointestinal haemmorhage
1%
dysgeusia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Recurrent or Metastatic Prostate Cancer (Cohort B)
High Risk Prostate Cancer (Cohort A)

Trial Design

1Treatment groups
Experimental Treatment
Group I: 18F-DCFPyLExperimental Treatment1 Intervention
A bolus of less than or equal to 9 mCi (331 MBq) of IV injection of 18F-DCFPyL
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
18F-DCFPyL Injection
2015
Completed Phase 3
~480

Find a Location

Who is running the clinical trial?

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLead Sponsor
557 Previous Clinical Trials
32,862 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,654 Previous Clinical Trials
40,933,115 Total Patients Enrolled
Steven Rowe, M.D., Ph.DPrincipal InvestigatorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could you provide a synopsis of the past research done on 18F-DCFPyL Injection?

"Currently, there are 18 studies looking into the efficacy of 18F-DCFPyL Injection. None of these trials have reached Phase 3 yet. Most experiments related to this treatment take place in Baltimore, Maryland though it is being studied at 27 different sites worldwide."

Answered by AI

To what disorders is 18F-DCFPyL Injection typically administered?

"18F-DCFPyL Injection is typically used to reduce levels of serum prostate specific antigen (psa), but can also be beneficial in treating suspected metastasis, positron emission tomography and recurrent cases of prostate cancer."

Answered by AI

Are participants being accepted into this research endeavor at the present time?

"Data found on clinicaltrials.gov shows that this trial is open for enrollment and has been since February 6th, 2015. The study was last revised on December 14th 2021."

Answered by AI

Has 18F-DCFPyL Injection obtained the endorsement of the Food and Drug Administration?

"Considering the limited data on 18F-DCFPyL Injection's efficacy and safety, our team gave it a score of 1."

Answered by AI

Does this research endeavor accept participants above the age of sixty?

"As per the trial's stipulations, participants must be aged 18 years or older and not exceed 100 to qualify for inclusion."

Answered by AI

What is the enrolment count for this research project?

"Indeed, clinicaltrials.gov affirms that this research project is currently in search of participants. This trial was posted on February 6th 2015 and recently updated on December 14th 2021. 50 individuals are needed for the purpose of the experiment at a single centre."

Answered by AI

Is it possible for me to participate in this research project?

"This research study is currently seeking 50 individuals with cancer in the age range of 18 to 100 years old. In order for patients to be eligible, they must possess a minimum chronologic maturity of eighteen years."

Answered by AI
~4 spots leftby Apr 2025